Rheumatology · Systemic Autoimmune Rheumatic Diseases
The facts most likely to be tested
Mixed Connective Tissue Disease is defined by the presence of high-titer anti-U1 RNP (ribonucleoprotein) antibodies in the absence of other specific autoantibodies.
Clinical presentation features an overlap syndrome combining characteristics of Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (Scleroderma), and Polymyositis.
Raynaud phenomenon is the most common initial clinical manifestation, often preceding other systemic symptoms by years.
Swollen, puffy fingers (sausage-like digits) are a classic, highly characteristic physical exam finding in patients with this condition.
Patients frequently exhibit inflammatory myositis characterized by proximal muscle weakness and elevated creatine kinase (CK) levels.
Pulmonary hypertension is the most serious and common cause of mortality in patients with long-standing disease.
Treatment for mild disease involves hydroxychloroquine or NSAIDs, while severe organ-threatening involvement requires systemic corticosteroids or immunosuppressants.
Vignette unlocked
A 34-year-old woman presents to the clinic with a 6-month history of painful, color-changing fingers upon cold exposure. She also reports diffuse swelling of her hands and persistent proximal muscle weakness when climbing stairs. Physical examination reveals puffy, sausage-like digits and mild tenderness in the quadriceps. Laboratory studies show a positive anti-U1 RNP antibody titer, while tests for anti-dsDNA, anti-Smith, and anti-Scl-70 are negative.
What is the most likely diagnosis?
Mixed Connective Tissue Disease (MCTD)
The patient presents with the classic triad of SLE, scleroderma, and polymyositis features, confirmed by the pathognomonic presence of high-titer anti-U1 RNP antibodies.
Full handout
High yield triage
Etiology / Epidemiology
Autoimmune overlap syndrome occurring primarily in young women. Characterized by high-titer anti-U1 RNP antibodies.
Clinical Manifestations
Features of SLE, systemic sclerosis, and polymyositis. Raynaud phenomenon is the earliest/most common finding.
Diagnosis
Diagnosis requires anti-U1 RNP antibodies and clinical features from at least two distinct connective tissue diseases.
Treatment
Corticosteroids are the mainstay of therapy. Avoid unnecessary immunosuppression without organ involvement.
Prognosis
Pulmonary hypertension is the leading cause of mortality. Monitor with echocardiogram and PFTs.
Full handout
Epidemiology & Etiology
MCTD is an autoimmune connective tissue disorder with a strong female predilection, typically presenting in the second to third decade of life. It is defined by the presence of high-titer antibodies against the U1 ribonucleoprotein (U1 RNP) complex. It is considered an overlap syndrome rather than a distinct entity by some, but remains a distinct clinical diagnosis on boards.
Pertinent Anatomy
The disease affects systemic connective tissues, specifically targeting the vasculature, skin, and musculoskeletal system. Involvement of the pulmonary vasculature is the most critical anatomical concern, leading to secondary pulmonary hypertension.
Pathophysiology
The hallmark is the production of anti-U1 RNP antibodies, which are highly sensitive and specific for this condition. These antibodies trigger immune complex deposition in various tissues, leading to systemic inflammation. The clinical phenotype evolves over time, often starting with Raynaud phenomenon and progressing to multi-organ involvement including synovitis and myositis.
Clinical Manifestations
Patients present with a combination of SLE (arthritis, malar rash), systemic sclerosis (sclerodactyly, esophageal dysmotility), and polymyositis (proximal muscle weakness). Raynaud phenomenon is nearly universal and often precedes other symptoms by years. Swollen, puffy fingers (sausage-like digits) are a classic physical exam finding. Pulmonary hypertension and interstitial lung disease are the most feared complications.
Diagnosis
The anti-U1 RNP antibody is the diagnostic requirement. Diagnosis is confirmed using the Alarcon-Segovia or Kasukawa criteria, which require high-titer anti-U1 RNP plus clinical features from at least two of the following: SLE, systemic sclerosis, or polymyositis. Pulmonary function tests (PFTs) with DLCO are essential for baseline screening.
Treatment
Management is tailored to the specific organ system involved. Corticosteroids are the first-line treatment for acute flares and inflammatory symptoms. For mild disease, hydroxychloroquine or NSAIDs may be sufficient. Immunosuppressants like methotrexate or azathioprine are reserved for refractory cases or organ-threatening disease. Pulmonary hypertension requires specialized vasodilator therapy.
Prognosis
The prognosis is generally better than SLE or systemic sclerosis, but pulmonary hypertension remains the primary cause of death. Patients require annual echocardiogram and PFTs to monitor for silent progression of lung disease.
Differential Diagnosis
SLE: Presence of anti-dsDNA and anti-Smith antibodies
Systemic Sclerosis: Presence of anti-Scl-70 or anti-centromere antibodies
Polymyositis: Isolated muscle inflammation without overlap features
Sjogren Syndrome: Presence of anti-Ro/SSA and anti-La/SSB antibodies
Rheumatoid Arthritis: Symmetric polyarthritis without systemic overlap features